EP Patent

EP2617719B1 — Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Assigned to Wyeth LLC · Expires 2016-05-11 · 10y expired

What this patent protects

Patent listed against neratinib-maleate.

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: EP2617719B1
Jurisdiction: EP
Classification: —
Expires: 2016-05-11
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.